dPCR Momentum Qiagen is expanding its QIAcuity digital PCR ecosystem with new gene expression assays, multiplexing capabilities, automation, and analysis tools to accelerate dPCR adoption across life sciences and biopharma. This creates sales opportunities to target research labs and CROs seeking higher sensitivity and standardized workflows, including environmental sample analysis applications.

Global Footprint With a large global team and 35+ locations serving hundreds of thousands of customers, there is potential to scale deployments of QIAcuity and sample-to-insight workflows across multi-site laboratories. Short-term opportunities include enterprise procurement programs and regional field engagement to accelerate adoption.

Automation Value Qiagen’s end-to-end automation solutions that tie sample processing, assay readiness and data analysis enable cost reductions and faster turnaround. Opportunities exist to upsell automation modules, workflow standardization, and integration services for new dPCR and diagnostic workflows in both research and clinical settings.

Diagnostics Growth The company serves molecular diagnostics and life sciences, aligning with growing demand in human healthcare diagnostics from hospitals, labs and biopharma partners. Sales potential includes expanding instrument and assay footprint in clinical labs, contract labs, and academia pursuing faster, more precise molecular tests and gene expression analyses.

Data Ecosystem Qiagen offers bioinformatics software and knowledge bases, plus TrackWise Digital and data integration capabilities. There is upside to selling data analysis tools, LIMS/LIS integration, cloud or on‑prem analytics subscriptions, and managed services that help customers turn raw molecular data into actionable insights.